RTS, S: Toward a first landmark on the Malaria Vaccine Technology Roadmap

Vaccine

Volumn 33, Issue 52, 2015, Pages 7425-7432

  Kaslow, David C ^a   Biernaux, Sophie ^b  

^a PATH   (United States)

^b GSK   (Belgium)

Author keywords

Circumsporozoite protein; Hepatitis B virus surface antigen; Malaria vaccines; Vaccine efficacy

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; HEPATITIS B SURFACE ANTIGEN; PROTOZOAL PROTEIN; RECOMBINANT VACCINE; RTS,S-AS01 VACCINE;

ADVISORY COMMITTEE; ARTICLE; CELLULAR IMMUNITY; DRUG APPROVAL; DRUG EFFICACY; DRUG LEGISLATION; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEBRILE CONVULSION; FINANCIAL MANAGEMENT; FOLLOW UP; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; MALARIA; MENINGITIS; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PUBLIC-PRIVATE PARTNERSHIP; RANDOMIZED CONTROLLED TRIAL (TOPIC); TONIC CLONIC SEIZURE; TREATMENT OUTCOME; VACCINATION; WORLD HEALTH ORGANIZATION; COST BENEFIT ANALYSIS; DRUG DEVELOPMENT; ECONOMICS; GENETICS; IMMUNIZATION; IMMUNOLOGY; INFANT; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; SECONDARY IMMUNIZATION;

CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DRUG DISCOVERY; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; MALARIA; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; VACCINATION; VACCINES, SYNTHETIC;

EID: 84951079707     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.061     Document Type: Article

References (46)

1. Cohen J., Nussenzweig V., Nussenzweig R., Vekemans J., Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin 2010, 90-96.
2. Casares S., Brumeanu T., Richie T. The RTS, S malaria vaccine. Vaccine 2010, 28:4880-4894.
3. Malaria Vaccine Technology Roadmap 2006. Available at: [accessed 31.01.15]. http://www.malariavaccine.org/files/Malaria_Vaccine_TRM_Final_000.pdf.
4. Malaria Vaccine Technology Roadmap 2013. Available at: [accessed 31.01.15]. http://www.who.int/immunization/topics/malaria/vaccine_roadmap/TRM_update_nov13.pdf?ua=1.
5. Miura K., Jongert E., Deng B., Zhou L., Lusingu J., Drakeley C., et al. Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes. Malar J 2014, 13:263.
6. E.M. Agency. Summary of opinion: Mosquirix-Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted); 23 July 2015. Available at: [accessed 21.08.15]. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/07/WC500190452.pdf.
7. Kappe S., Vaughn A., Boddey J., Cowman A. That was then but this is now: malaria research in the time of an eradication agenda. Science 2010, 328:862-866.
8. Offeddu V., Thathy V., Marsh K., Matuschewski K. Naturally acquired immune responses against Plasmodium falciparum sporozoites and liver infection. Int J Parasitol 2012, 42:535-548.
9. Sardá V., Williamson K., Kaslow D. Approaches to malaria vaccine development using the retrospectroscope. Infect Immun 2009, 77:3130-3140.
10. Coppi A., Natarajan R., Pradel G., Bennett B., James E., Roggero M., et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J Exp Med 2011, 208:341-356.
11. Singh A., Buscaglia C., Wang Q., Levay A., Nussenzweig D., Walker J., et al. Plasmodium circumsporozoite protein promotes the development of the live stages of the parasite. Cell 2007, 131:492-504.
12. Kumar K., Sano G., Boscardin S., Nussenzweig R., Nussenzweig M., Zavala F., et al. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 2006, 444:937-940.
13. Ferguson D.J.P., Balaban A.E., Patzewitz E.-M., Wall R.J., Hopp C.S., Poulin B., et al. The repeat region of the circumsporozoite protein is critical for sporozoite formation and maturation in plasmodium. PLOS ONE 2014, 9:e113923.
14. Crompton P., Pierce S., Miller L. Advances and challenges in malaria vaccine development. J Clin Investig 2010, 120:4168-4178.
15. Leroux-Roels G., Leroux-Roels I., Clement F., Ofori-Anyinam O., Lievens M., Jongert E., et al. Evaluation of the immune response to RTS, S/AS01 and RTS, S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults. Hum Vaccin Immunother 2014, 10:2211-2219.
16. Didierlaurent A., Collignon C., Bourguignon P., Wouters S., Fierens K., Fochesato M., et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol 2014, 193:1920-1930.
17. Segal L., Morelle D., Blee M., Moore E., Damsten M., Liu K.C., et al. Local tolerance and systemic toxicity of single and repeated intramuscular administrations of two different formulations of the RTS, S malaria candidate vaccine in rabbits. Regul Toxicol Pharmacol 2014, 71:269-278.
18. Bongfen S., Ntsama P., Offner S., Smith T., Felger I., Tanner M., et al. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 2009, 27:328-335.
19. Gandhi K., Thera M., Coulibaly D., Traoré K., Guindo A., Ouattara A., et al. Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications. PLOS ONE 2014, e101783.
20. Zeeshan M., Alam M., Vinayak S., Bora H., Tyagi R., Alam M., et al. Genetic variation in the Plasmodium falciparum circumsporozoite protein in India and its relevance to RTS, S malaria vaccine. PLoS ONE 2012, 7:e43430.
21. RTS, S Phase III Malaria Vaccine Trial initiative, Broad Institute (broadinstitute.org); Available at: [accessed 31.01.2015]. https://olive.broadinstitute.org/projects/RTS_S_phase_III_malaria_vaccine_trial.
22. Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa. Available at: [accessed 31.01.15]. https://clinicaltrials.gov/ct2/show/NCT00866619?term=GSK+malaria+vaccine+257049%26rank=6.
23. Efficacy of GSK Biologicals' candidate malaria vaccine (257049) against malaria disease caused by P. falciparum infection in infants and children in Africa. Available at: [accessed 31.01.15]. http://www.gsk-clinicalstudyregister.com/study/110021.
24. Vekemans J., Marsh K., Greenwood B., Leach A., Kabore W., Soulanoudjingar S., et al. Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care. Malar J 2011, 10:221.
25. Lievens M., Aponte J., Williamson J., Mmbando B., Mohamed A., Bejon P., et al. Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children. Malar J 2011, 10:222.
26. Swysen C., Vekemans J., Bruls M., Oyakhirome S., Drakeley C., Kremsner P., et al. Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J 2011, 10:223.
27. Leach A., Vekemans J., Lievens M., Ofori-Anyinam O., Cahill C., Owusu-Agyei S., et al. Design of a phase III multicenter trial to evaluate the efficacy of the RTS, S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J 2011, 10:224.
28. Angwenyi V., Kamuya D., Mwachiro D., Kalama B., Marsh V., Njuguna P., et al. Complex realities: community engagement for a paediatric randomized controlled malaria vaccine trial in Kilifi, Kenya. Trials 2014, 25:65.
29. Umeh R., Oguche S., Oguonu T., Pitmang S., Shu E., Onyia J., et al. Immunogenicity and safety of the candidate RTS, S/AS01 vaccine in young Nigerian children: a randomized, double-blind, lot-to-lot consistency trial. Vaccine 2014, 32:6556-6562.
30. RTS, S/AS01 vaccine summary of ongoing/planned studies; March 2013. Available at: [accessed 10.02.15]. http://www.who.int/immunization/sage/meetings/2013/april/5_RTSS_tables_for_SAGE_and_MPAC-_final.pdf.
31. Partnership R.C.T. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365:1863-1875.
32. R.C.T. Partnership A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367:2284-2295.
33. R.C.T. Partnership Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLOS Med 2014, 11.
34. S.C.T.P. RTS Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015, 386:31-45.
35. Gessner B., Feikin D. Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy. Vaccine 2014, 32:3133-3138.
36. Campo J., Dobaño C., Sacarlal J., Guinovart C., Mayor A., Angov E., et al. Impact of the RTS, S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens. PLoS ONE 2011, 6:e25779.
37. Olotu A., Moris P., Mwacharo J., Vekemans J., Kimani D., Janssens M., et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS, S/AS01E and protection against P. falciparum clinical malaria. PLoS ONE 2011, 6:e25786.
38. Olotu A., Clement F., Jongert E., Vekemans J., Njuguna P., Ndungu F., et al. Avidity of anti-circumsporozoite antibodies following vaccination with RTS, S/AS01E in young children. PLOS ONE 2014, 9:e115126.
39. White M., Bejon P., Olotu A., Griffin J., Bojang K., Lusingu J., et al. A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS, S malaria vaccine. BMC Med 2014, 12:117.
40. Campo J., Aponte J., Skinner J., Nakajima R., Molina D., Liang L., et al. RTS, S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver and blood stage parasites. Mol Cell Proteomics 2014, 14:519-531.
41. GSK announces EU regulatory submission for malaria vaccine candidate RTS, S. Available at: [accessed 31.01.15]. http://www.gsk.com/en-gb/media/press-releases/2014/gsk-announces-eu-regulatory-submission-for-malaria-vaccine-candidate-rtss/.
42. W.M.P.A.C.a. Secretariat Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of fifth biannual meeting (March 2014). Malar J 2014, 13:253.
43. Questions and answers on malaria vaccines; October 2013. Available at: [accessed 10.02.15]. http://www.who.int/immunization/research/development/malaria_vaccine_qa/en/.
44. Meeting of the Strategic Advisory Group of Experts on immunization, April 2013-conclusions and recommendation. World Health Org Wkly Epidemiol Rec 2013, 20(88):214-216.
45. Report to the GAVI Alliance Board; 21-22 November 2013 [accessed 10.02.15].
46. Malaria Vaccine Investment Strategy Background Document #3; November 2013. Available at: [accessed 10.02.15]. http://www.gavi.org/Library/Documents/GAVI-documents/Strategy/Final-VIS-analysis-2013--Malaria/.